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Abstract
Objective: Apparent diffusion coefficients (ADC) can help differentiate between central nervous system (CNS) lymphoma
and Glioblastoma (GBM). However, overlap between ADCs for GBM and lymphoma have been reported because of various
region of interest (ROI) methods. Our aim is to explore ROI method to provide the most reproducible results for
differentiation.
Materials and Methods: We studied 25 CNS lymphomas and 62 GBMs with three ROI methods: (1) ROI1, whole tumor
volume; (2) ROI2, multiple ROIs; and (3) ROI3, a single ROI. Interobserver variability of two readers for each method was
analyzed by intraclass correlation(ICC). ADCs were compared between GBM and lymphoma, using two-sample t-test. The
discriminative ability was determined by ROC analysis.
Results: ADCs from ROI1 showed most reproducible results (ICC .0.9). For ROI1, ADCmean for lymphoma showed
significantly lower values than GBM (p = 0.03). The optimal cut-off value was 0.9861023 mm2/s with 85% sensitivity and
90% specificity. For ROI2, ADCmin for lymphoma was significantly lower than GBM (p= 0.02). The cut-off value was
0.6961023 mm2/s with 87% sensitivity and 88% specificity.
Conclusion: ADC values were significantly dependent on ROI method. ADCs from the whole tumor volume had the most
reproducible results. ADCmean from the whole tumor volume may aid in differentiating between lymphoma and GBM.
However, multi-modal imaging approaches are recommended than ADC alone for differentiation.
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Introduction
Glioblastoma (GBM) is the most commonmalignant brain tumor
in adults. GBM is marked by rapid growth [1]. Primary central
nervous system(CNS) lymphoma is less common than GBM but its
incidence is increasing [2]. For GBM, surgical resection is the
primary treatment [3], while chemotherapy or radiation therapy is
the treatment of choice for CNS lymphoma [4]. Therefore, an exact
differential diagnosis is essential for making therapeutic decisions
about GBM and CNS lymphoma. On conventional imaging,
primary CNS lymphomas usually show homogenous and intense
contrast enhancement. And primary CNS lymphomas are often
hypointense to gray matter without large necrosis on T2-weighted
image(T2WI) [5]. However, differentiation is often difficult because
some of GBMs have considerable overlap in conventional magnetic
resonance(MR) imaging findings [6].
Several studies have shown that apparent diffusion coefficient
(ADC) values from diffusion-weighted imaging(DWI) can help
differentiate between CNS lymphoma and GBM [7–9]. However,
other studies have reported that ADC might not be helpful
because of substantial overlap between values for CNS lymphoma
and GBM [10,11].
These contradictory results are partly because ADC can be
measured by a variety of methods to determine placement of the
region of interest (ROI). Toh et al [9] drew the ROI in the center of
the solid enhancing region Yamashita et al [12] and Doskaliyev et al
[13] drew several small ROIs within the tumor. This might
contribute to the wide variety in reported ADC results. Thus, it is
necessary to evaluate the reliability of commonly used ROI methods
in DWI. The purpose of this study was to compare whole tumor
volume ROI, multiple ROIs and single ROI for ADCmeasurement
for differentiating between primary CNS lymphoma and GBM.
Materials and Methods
Patients
Approval by Severance hospital institutional review board was
obtained and informed consent was waived for this retrospective
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study. Patients’ records and information were anonymized and de-
identified prior to analysis. MR imaging of consecutive patients
from Oct 2012 through Nov 2013 were retrospectively analyzed.
We identified 30 immunocompetent patients with biopsy-proven
primary CNS lymphoma. We excluded the 5 patients with
primary CNS lymphoma because they received the steroid therapy
before they performed MR imaging. Finally, 25 patients with
primary CNS lymphoma (15 women, 10 men; mean age, 60 years;
age range, 44–77 years) were included. We identified 62 patients
(28 women and 34 men;mean age, 56.72 years; age range, 32–73
years) with histologically-confirmed, World Health Organization
grade IV GBM in our medical record.
MR imaging
All images were obtained using a 3.0T MRI scanner (Achieva,
Philips Medical system, Best, Netherlands) with a 16-channel
sensitivity encoding (SENSE) head coil. Diffusion weighted
image(DWI) was performed using a single-shot spin-echo (SE)
echo planar sequence with following parameters: Echo time(TR)/
Repetition time(TE) = 8413/77 ms, 90u flip angle, 70 transverse
sections, SENSE factor = 2, slice thickness = 2 mm, 1126112
matrix, field of view(FOV)= 220 mm. Diffusion-sensitizing gradi-
ents were applied sequentially in the x, y and z directions with b
factors of 0 and 1000 s/mm2. ADCs were automatically calculated
by the operating console of the MR scanner and displayed as
corresponding ADC maps.
Postcontrast T1-weighted 3D-gradient echo sequence(GRE)
imaging was obtained with following parameters: TR/TE=9.86/
4.59 ms, flip angle, 8u, 2246224 matrix with 224 phase-encoding
steps; 1-mm section thickness; and 220 mm FOV. A standard dose
(0.1 mmol/kg body weight) of gadoteric acid (Gd-DOTA,
Dotarem; Laboratoire Guerbet, Aulnay-sous-Bois, France) was
injected intravenously. Routine anatomic precontrast T1/T2
images were also obtained.
Image analysis
The size and location of tumor was recorded by the study
coordinator. If there were multiple lesions, the largest one was
measured. Three different ADC measurements for one lesion were
obtained from the ADC map according to three distinct ROI
protocols: (1) whole tumor volume; (2) multiple ROIs and (3) single
ROI. For whole tumor volume, using the coregistration module
integrated in the commercial software nordicICE (Nordic Imaging
Lab, Bergen, Norway), ADC maps were coregistered to post-
contrast T1-weighted 3D GRE image by the study coordinator.
Two readers (a neuroradiologist with 5 years of experience and a
neuroradiologist with 14 years of experience) independently drew
freehand ROIs along tumor borders on coregistered images to
cover tumors completely with consecutive slices. Minimum,
maximum and mean value (min, max and mean) were calculated
from ADC values from the whole tumor volume. For multiple
ROIs, two readers independently drew circular 5 ROIs
(area = 10 mm2) on enhancing lesions in coregistered ADC map.
For single ROI method, the readers reviewed the coregistered
ADC maps and drew a single circular ROI (area = 20 mm2) on
any enhancing portion. Hemorrhage, cyst and necrosis were
avoided when drawing all three ROI methods (Fig. 1). Min, max
and mean were calculated as above.
Statistical analysis
Statistical analyses were performed using SPSS version 16.0
(SPSS Inc., Chicago, IL, USA). Interobserver variability of the
readers for different ROI methods was calculated as intraclass
correlation(ICC) coefficient (0.00–0.20 poor, 0.21–0.40 fair, 0.41–
0.60 moderate, 0.61–0.80 good and 0.81–1.00 excellent correla-
tion). ADCs were averaged between the two observers for further
analysis. ADCmin, ADCmax and ADCmean were compared
between GBM and lymphoma using a two-sample t-test for each
individual ROI method. Sensitivity, specificity and accuracy for
the discriminating between GBM and lymphoma were calculated
for each parameter using an optimal cut-off value determined by
receiver operating characteristic (ROC) analysis. Area-under-the-
ROC curve (AUC) values for discrimination were calculated for
the four parameters. P-values,0.05 were considered statistically
significant.
Results
The most frequent location of primary CNS lymphoma was the
cerebral hemisphere (13 out of 25, 52%), followed by the corpus
callous (7 out of 25, 26%), deep nuclei (4 out of 25, 18%) and deep
white matter (1 out of 25, 4%). The mean size of primary CNS
lymphoma was 26.4 mm (range, 16,54 mm). The most frequent
location of GBM was the cerebral hemisphere (34 out of 62, 55%),
followed by the deep nuclei (12 out of 62, 20%), corpus callosum (9
out of 62, 14%) and deep white matter (7 out of 62, 11%). The
mean size of GBM was 30.3 mm (range, 9,50 mm).
Interobserver variability
Intraclass correlation coefficients between two readers for three
ROI methods are in Table 1. ADCmin, ADCmax, ADCmean from
Figure 1. Representative case. A 43-year-old female with biopsy
proven GBM. On Gd enhanced T1-weighed image (A), GBM shows
heterogeneous enhancement in the left basal ganglia. ADC maps were
coregistered to Gd enhanced T1-weighted image. Whole tumor volume
ROI (ROI1) was drawn along the tumor border for each consecutive slice
of the coregistered image (B). Multiple circular ROIs (ROI2) were drawn
on coregistered image (area = 10 mm2) (C). A single circular ROI (ROI3)
was drawn on any solid area, avoiding necrosis (area = 20 mm2) in
coregistered image (D).
doi:10.1371/journal.pone.0112948.g001
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whole tumor volumes showed excellent interobserver reproduc-
ibility (ICC=0.94, 0.92, 0.96 respectively). ADCmin, ADCmax,
ADCmean obtained from multiple ROIs showed good to excellent
interobserver reproducibility (ICC=0.86, 0.81, 0.78 respectively).
ADCmin, ADCmax, ADCmean from ROI3 showed good interob-
server reproducibility (ICC=0.69, 0.74, 0.72 respectively).
Comparison of GBM and lymphoma ADC variables
ADC measures for the three different ROI protocols are in
Table 2. For ROI1, whole tumor volume, ADCmean of lymphomas
was significantly lower than ADCmean for GBM
((0.8760.18)61023 mm2/s vs. (1.2860.24)61023 mm2/s,
p = 0.03). However, differences in ADCmin and ADCmax were
not significant between GBM and lymphoma (p.0.05). For ROI2,
ADCmin was significantly lower for lymphoma than for GBM
((0.5160.17)61023 mm2/s vs. (0.7960.20)61023 mm2/s,
p = 0.02). However, differences in ADCmax and ADCmean were
not significantly different between GBM and lymphoma (p.0.05).
For ROI3, ADC variables were not significantly different between
GBM and lymphoma (p.0.05).
ROC analysis
ADC variables from three different ROI methods were
evaluated for discriminative ability using ROC analysis (Table 3).
ADC mean calculated from ROI1 was a significant predictor for
differentiating lymphoma from GBM (p=0.03). The optimal cut-
off value was 0.9861023 mm2/s (sensitivity: 85%; specificity:
90%; AUC, 0.87). In ROI2, ADCmin was a significant predictor
for differentiating lymphoma from GBM (p= 0.02). The optimal
cutoff value was 0.7261023 mm2/s (sensitivity: 87%; specificity:
65%; accuracy: 0.84). Other variables from the three different
ROI methods did not show significant discriminative ability (p.
0.05).
Discussion
Previous studies have used various ROI methods to measure
ADC values for differentiating between lymphoma and GBM [7–
10]. Toh et al [9] drew a single ROI in the center of solid
enhancing region and Yamashita et al [12] and Doskaliyev et al
[13] drew several small ROIs. Kang et al [14] used the whole
tumor volume ROI. These various ROI methods may account for
previous inconsistent results. However, there has been no study
comparing the reproducibility of various ROI selections. Accord-
ing to our results, interobserver reproducibility of ADC calcula-
tions was dependent on the selected ROI method. ADC
measurements from the whole tumor volume (ROI1) were most
reproducible followed by multiple ROIs, then by the single ROI
method. Several studies reported that quantitative measurement
from the whole tumor volume is the most reproducible, although
Table 1. Interobserver variability measured as intraclass correlation coefficient for different ROI protocols.
ROI protocols
ROI1 ROI2 ROI3
ADCmin(10
23 mm2/s) 0.94 0.86 0.69
ADCmax 0.92 0.81 0.74
ADCmean 0.96 0.78 0.72
ROI, region of interest; ADC, apparent diffusion coefficients;min, minimum; max, maximum.
Number presents intraclass correlation coefficients: 0.00–0.20, poor; 0.21–0.40, fair; 0.41–0.60, moderate; 0.61–0.80, good; 0.81–1.00, excellent correlation.
ROI1 indicates whole tumor volume; ROI2, multiple ROIs; ROI3, a single ROI method(any enhancing portion avoiding cyst).
doi:10.1371/journal.pone.0112948.t001
Table 2. ADC variables for lymphoma and GBM using three different ROI methods.
Variable Lymphoma GBM p
ROI1
Min(1023 mm2/s) 0.4160.18 0.4860.15 0.37
Max 2.1660.53 2.4560.64 0.24
Mean 0.8760.18 1.2860.24 0.03*
ROI2
Min 0.5160.17 0.7960.20 0.02*
Max 1.0260.24 1.0460.28 0.34
Mean 0.7360.20 0.8560.17 0.25
ROI3
Min 0.6660.13 0.8060.28 0.16
Max 0.9160.20 0.9860.25 0.47
Mean 0.7960.15 0.8960.25 0.25
ROI, region of interest; ADC, apparent diffusion coefficients;min, minimum; max, maximum; SD, standard deviation; GBM, glioblastoma.
ROI1 indicates whole tumor volume; ROI2, most enhancing portion; ROI3, conventional ROI method(any enhancing portion avoiding cyst).
*indicates statistical significance (p,0.05).
doi:10.1371/journal.pone.0112948.t002
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their subjects was not the brain [15–17]. Our results suggested that
the whole tumor volume ROI method is favored, and single ROI
method should be avoided when measuring ADC values. A single
ROI method can be subjective and prone to a sampling bias [18].
We found that the ADCmean from the whole tumor volume was
significantly lower for lymphoma than for GBM. Meanwhile,
ADCmean from multiple ROIs or a single ROI was not
significantly different between lymphoma and GBM. It is well
known that GBM may have heterogeneous histologic features.
Although we draw ROIs avoiding large necrosis, GBM may have
microscopic necrosis with surrounding clustered nuclei, so called
‘‘pseudopalisading’’ features, which may increase the overall
ADCmean [19,20]. These features make it easier to differentiate
between lymphoma and GBM. On the contrary, an ADC from
multiple ROIs or a single ROI may not reflect heterogeneity of
GBM [21].
Also of note was that ADCmin from the whole tumor volume
was not a significant predictor but ADCmin from multiple ROIs
was a significant predictor for differentiating between lymphoma
and GBM. ADCmin has been suggested to reflect the highest
tumor cell density or the most proliferative portion of a tumor
within heterogeneous tumors. ADCmin from whole tumor volumes
might be influenced by the susceptibility of MR to generate
artifacts from blood products and might not represent true
ADCmin of the tumor parenchyma.
However, our results should be carefully interpreted, because
the ranges of ADCs between lymphoma and GBM still
substantially overlapped (Fig. 2) and ADC alone might not be
sufficient to differentiate lymphoma from GBM. Other advanced
imaging techniques such as dynamic contrast-enhanced MRI
(DCE), dynamic susceptibility-weighted imaging (DSC), suscepti-
bility-weighted imaging (SWI) and FDG-PET have been reported
to improve differential diagnosis of lymphoma and GBM [22–25].
Kickingereder et al [26] reported multimodal imaging integrating
these advanced sequences allowed reliable differentiation of
lymphoma and GBM. Therefore, Multiple advanced imaging
techniques in conjunction with ADC should be preferred than
ADC alone when differentiating lymphoma from GBM.
Our study has limitations. First, selection bias was ineluctable in
this study because only the patients who had pathologically proven
lymphoma and GBM were enrolled. Second, it was difficult to
spatially co-localize pathology with MR images. Therefore,
Table 3. Sensitivity and specificity of ADC variables for differentiating lymphoma from GBM using ROC.
Variable Cut off value Sensitivity Specificity AUC p
ROI1
Min(1023 mm2/s) 0.47 42 90 0.58 0.50
Max 2.52 41 92 0.63 0.28
Mean 0.98 85 90 0.87 0.01*
ROI2
Min 0.69 87 88 0.84 0.02*
Max 1.04 85 45 0.64 0.21
Mean 0.83 50 90 0.70 0.06
ROI3
Min 0.79 85 63 0.70 0.09
Max 1.07 85 54 0.59 0.44
Mean 0.90 85 54 0.64 0.24
ROI, region of interest; ADC, apparent diffusion coefficients; min, minimum; max, maximum; SD, standard deviation; GBM, glioblastoma; AUC, area-under-the-ROC curve.
ROI1 indicates whole tumor volume; ROI2, most enhancing portion; ROI3, conventional ROI method(any enhancing portion avoiding cyst).
*indicates statistical significance (p,0.05).
doi:10.1371/journal.pone.0112948.t003
Figure 2. Box-and-whisker plots of representative ADC variables for lymphoma and GBM: mean ADC in ROI1 (A) and minimum ADC
in ROI2 (B). The central box represents the value from the lower to upper quartile. The middle line represents the median. The horizontal line
extends from the minimum to the maximum value. An outside value are plotted with s square marker.
doi:10.1371/journal.pone.0112948.g002
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interpreting the pathological meaning of ADC from each ROI was
difficult. Third, the number of cases was not enough to draw a
solid conclusion. Fourth, we did not perform ADC histogram
analysis and the distribution of ADCs were not assessed.
In conclusion, ADC values were significantly dependent on
ROI method. ADCs from the whole tumor volume had the most
reproducible results. ADCmean from the whole tumor volume may
aid in differentiating between lymphoma and GBM. However,
multi-modal imaging approaches are recommended than ADC
alone for the differentiation.
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